Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma
Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation...
Gespeichert in:
Veröffentlicht in: | International journal of clinical practice (Esher) 2021-02, Vol.75 (2), p.e13593-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 2 |
container_start_page | e13593 |
container_title | International journal of clinical practice (Esher) |
container_volume | 75 |
creator | Akkiz, Hikmet Carr, Brian I. Bag, Harika G. Karaoğullarından, Ümit Yalçın, Kendal Ekin, Nazim Özakyol, Ayşegül Altıntaş, Engin Balaban, Hatice Y. Şimşek, Halis Uyanıkoğlu, Ahmet Balkan, Ayhan Kuran, Sedef Üsküdar, Oğuz Ülger, Yakup Güney, Burak Delik, Anil |
description | Introduction
Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
Objective
To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
Methods
We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
Results
Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
Conclusions
Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs. |
doi_str_mv | 10.1111/ijcp.13593 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7758189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479584547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</originalsourceid><addsrcrecordid>eNp9kU9rFDEYh4MotlYvfgAJeBOnJpNkk70IslStFCxt7-GdzBs3a2ayJjNbFvzwpm4tejGX_Ht48gs_Ql5ydsrreBc2bnvKhVqKR-SYa9k2vJX8cV2LhWkUE_yIPCtlw1irlGFPyZFolRFyKY_Jz2vM80Aj7jAWmjwNo48wDDClvKcD5O-YC11dXb6lZ9dXFMaeQuzmIYyVpBkjTCGNdEq0zHkXdhCpT5lu6zGOU6G3YVrTNdZ9chjjHCFTB9mFMQ3wnDzxEAu-uJ9PyM3Hs5vV5-bi66fz1YeLxklpRKNV62EhOrfwhvVsgU6rDnvWedlxD-iFQMGZYsah9sxBxwww3XPoDXMoTsj7g3Y7dwP2rgbLEO02h_q_vU0Q7L83Y1jbb2lntVaGm2UVvL4X5PRjxjLZTZrzWCPbVuqlMlJJXak3B8rlVEpG__ACZ_auKHtXlP1dVIVf_Z3pAf3TTAX4AbgNEff_UdnzL6vLg_QX6VOiHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479584547</pqid></control><display><type>article</type><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</creator><creatorcontrib>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</creatorcontrib><description>Introduction
Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
Objective
To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
Methods
We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
Results
Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
Conclusions
Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.13593</identifier><identifier>PMID: 32583494</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Albumin ; Albumins ; Biomarkers ; C-Reactive Protein ; Carcinoma, Hepatocellular ; Hepatocellular carcinoma ; Humans ; Inflammation ; Liver cancer ; Liver Neoplasms ; Portal vein ; Retrospective Studies ; Serum levels ; Survival ; Thrombosis ; Tumors</subject><ispartof>International journal of clinical practice (Esher), 2021-02, Vol.75 (2), p.e13593-n/a</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</citedby><cites>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</cites><orcidid>0000-0002-0901-9192 ; 0000-0002-6111-5077</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.13593$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.13593$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32583494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akkiz, Hikmet</creatorcontrib><creatorcontrib>Carr, Brian I.</creatorcontrib><creatorcontrib>Bag, Harika G.</creatorcontrib><creatorcontrib>Karaoğullarından, Ümit</creatorcontrib><creatorcontrib>Yalçın, Kendal</creatorcontrib><creatorcontrib>Ekin, Nazim</creatorcontrib><creatorcontrib>Özakyol, Ayşegül</creatorcontrib><creatorcontrib>Altıntaş, Engin</creatorcontrib><creatorcontrib>Balaban, Hatice Y.</creatorcontrib><creatorcontrib>Şimşek, Halis</creatorcontrib><creatorcontrib>Uyanıkoğlu, Ahmet</creatorcontrib><creatorcontrib>Balkan, Ayhan</creatorcontrib><creatorcontrib>Kuran, Sedef</creatorcontrib><creatorcontrib>Üsküdar, Oğuz</creatorcontrib><creatorcontrib>Ülger, Yakup</creatorcontrib><creatorcontrib>Güney, Burak</creatorcontrib><creatorcontrib>Delik, Anil</creatorcontrib><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Introduction
Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
Objective
To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
Methods
We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
Results
Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
Conclusions
Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</description><subject>Albumin</subject><subject>Albumins</subject><subject>Biomarkers</subject><subject>C-Reactive Protein</subject><subject>Carcinoma, Hepatocellular</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Liver cancer</subject><subject>Liver Neoplasms</subject><subject>Portal vein</subject><subject>Retrospective Studies</subject><subject>Serum levels</subject><subject>Survival</subject><subject>Thrombosis</subject><subject>Tumors</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rFDEYh4MotlYvfgAJeBOnJpNkk70IslStFCxt7-GdzBs3a2ayJjNbFvzwpm4tejGX_Ht48gs_Ql5ydsrreBc2bnvKhVqKR-SYa9k2vJX8cV2LhWkUE_yIPCtlw1irlGFPyZFolRFyKY_Jz2vM80Aj7jAWmjwNo48wDDClvKcD5O-YC11dXb6lZ9dXFMaeQuzmIYyVpBkjTCGNdEq0zHkXdhCpT5lu6zGOU6G3YVrTNdZ9chjjHCFTB9mFMQ3wnDzxEAu-uJ9PyM3Hs5vV5-bi66fz1YeLxklpRKNV62EhOrfwhvVsgU6rDnvWedlxD-iFQMGZYsah9sxBxwww3XPoDXMoTsj7g3Y7dwP2rgbLEO02h_q_vU0Q7L83Y1jbb2lntVaGm2UVvL4X5PRjxjLZTZrzWCPbVuqlMlJJXak3B8rlVEpG__ACZ_auKHtXlP1dVIVf_Z3pAf3TTAX4AbgNEff_UdnzL6vLg_QX6VOiHQ</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Akkiz, Hikmet</creator><creator>Carr, Brian I.</creator><creator>Bag, Harika G.</creator><creator>Karaoğullarından, Ümit</creator><creator>Yalçın, Kendal</creator><creator>Ekin, Nazim</creator><creator>Özakyol, Ayşegül</creator><creator>Altıntaş, Engin</creator><creator>Balaban, Hatice Y.</creator><creator>Şimşek, Halis</creator><creator>Uyanıkoğlu, Ahmet</creator><creator>Balkan, Ayhan</creator><creator>Kuran, Sedef</creator><creator>Üsküdar, Oğuz</creator><creator>Ülger, Yakup</creator><creator>Güney, Burak</creator><creator>Delik, Anil</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0901-9192</orcidid><orcidid>https://orcid.org/0000-0002-6111-5077</orcidid></search><sort><creationdate>202102</creationdate><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><author>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Albumin</topic><topic>Albumins</topic><topic>Biomarkers</topic><topic>C-Reactive Protein</topic><topic>Carcinoma, Hepatocellular</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Liver cancer</topic><topic>Liver Neoplasms</topic><topic>Portal vein</topic><topic>Retrospective Studies</topic><topic>Serum levels</topic><topic>Survival</topic><topic>Thrombosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akkiz, Hikmet</creatorcontrib><creatorcontrib>Carr, Brian I.</creatorcontrib><creatorcontrib>Bag, Harika G.</creatorcontrib><creatorcontrib>Karaoğullarından, Ümit</creatorcontrib><creatorcontrib>Yalçın, Kendal</creatorcontrib><creatorcontrib>Ekin, Nazim</creatorcontrib><creatorcontrib>Özakyol, Ayşegül</creatorcontrib><creatorcontrib>Altıntaş, Engin</creatorcontrib><creatorcontrib>Balaban, Hatice Y.</creatorcontrib><creatorcontrib>Şimşek, Halis</creatorcontrib><creatorcontrib>Uyanıkoğlu, Ahmet</creatorcontrib><creatorcontrib>Balkan, Ayhan</creatorcontrib><creatorcontrib>Kuran, Sedef</creatorcontrib><creatorcontrib>Üsküdar, Oğuz</creatorcontrib><creatorcontrib>Ülger, Yakup</creatorcontrib><creatorcontrib>Güney, Burak</creatorcontrib><creatorcontrib>Delik, Anil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akkiz, Hikmet</au><au>Carr, Brian I.</au><au>Bag, Harika G.</au><au>Karaoğullarından, Ümit</au><au>Yalçın, Kendal</au><au>Ekin, Nazim</au><au>Özakyol, Ayşegül</au><au>Altıntaş, Engin</au><au>Balaban, Hatice Y.</au><au>Şimşek, Halis</au><au>Uyanıkoğlu, Ahmet</au><au>Balkan, Ayhan</au><au>Kuran, Sedef</au><au>Üsküdar, Oğuz</au><au>Ülger, Yakup</au><au>Güney, Burak</au><au>Delik, Anil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-02</date><risdate>2021</risdate><volume>75</volume><issue>2</issue><spage>e13593</spage><epage>n/a</epage><pages>e13593-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Introduction
Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
Objective
To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
Methods
We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
Results
Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
Conclusions
Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>32583494</pmid><doi>10.1111/ijcp.13593</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0901-9192</orcidid><orcidid>https://orcid.org/0000-0002-6111-5077</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1368-5031 |
ispartof | International journal of clinical practice (Esher), 2021-02, Vol.75 (2), p.e13593-n/a |
issn | 1368-5031 1742-1241 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7758189 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Albumin Albumins Biomarkers C-Reactive Protein Carcinoma, Hepatocellular Hepatocellular carcinoma Humans Inflammation Liver cancer Liver Neoplasms Portal vein Retrospective Studies Serum levels Survival Thrombosis Tumors |
title | Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A38%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20inflammatory%20markers%20CRP,%20ESR%20and%20albumin%20in%20relation%20to%20survival%20for%20patients%20with%20hepatocellular%20carcinoma&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Akkiz,%20Hikmet&rft.date=2021-02&rft.volume=75&rft.issue=2&rft.spage=e13593&rft.epage=n/a&rft.pages=e13593-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.13593&rft_dat=%3Cproquest_pubme%3E2479584547%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479584547&rft_id=info:pmid/32583494&rfr_iscdi=true |